UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report Pursuant to

Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):

November 1, 2010

 

IRONWOOD PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-34620

 

04-3404176

(State of incorporation
or organization)

 

(Commission file number)

 

(I.R.S. Employer
Identification Number)

 

301 Binney Street
Cambridge, Massachusetts

 

02142

(Address of principal
executive offices)

 

(Zip code)

 

(617) 621-7722

(Registrant’s telephone number,

including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 8.01  Other Events.

 

On November 1, 2010, Ironwood Pharmaceuticals, Inc. issued a separate press release with each of Forest Laboratories, Inc. and Almirall, S.A. announcing positive top-line results from the second Phase 3 clinical trial assessing the efficacy and safety of the investigational drug, linaclotide, in patients with irritable bowel syndrome with constipation.   The press releases are attached hereto as Exhibit 99.1 and Exhibit 99.2 and are incorporated herein by reference.

 

Item 9.01  Financial Statements and Exhibits.

 

(d)   Exhibits.

 

Exhibit No.

 

Description

 

 

 

99.1

 

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. Press Release dated November 1, 2010

 

 

 

99.2

 

Almirall, S.A. and Ironwood Pharmaceuticals, Inc. Press Release dated November 1, 2010

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Ironwood Pharmaceuticals, Inc.

 

 

 

 

 

Dated: November 2, 2010

By:

/s/ Michael J. Higgins

 

 

Name:

Michael J. Higgins

 

 

Title:

Chief Operating Officer and Chief Financial Officer

 

3